Meningocortical lesion increases expression of the cholecystokinin gene in rat cerebral cortex: evidence for the involvement of platelet-activating factor (PAF)

Platelet-activating factor in the CNS

Platelet-activating factor (PAF) is a phospholipid synthesized in a variety of cells throughout the body. Platelet-activating factor has been identified in the CNS and has a number of diverse physiological and pathological functions. It has been shown to be a modulator of many CNS processes, ranging from long-term potentiation (LTP) to neuronal differentiation. Excessive levels of PAF appear to play an important role in neuronal cell injury, such as that resulting from ischaemia, inflammation, human immunodeficiency syndrome (HIV) and meningitis. The beneficial effects of PAF receptor antagonists are many and give rise to possible therapeutic strategies for neurotrauma.

Changes in hypothalamic cholecystokininA and cholecystokininB receptor subtypes and associated neuropeptide expression in response to salt-stress in the rat and mouse

This study demonstrates cholecystokinin receptor plasticity in response to salt-loading in the rat and mouse hypothalamus. It identifies, for the first time, the cholecystokinin receptor subtypes involved, firstly by receptor autoradiography and secondly by in situ hybridization. Both species showed increases in hypothalamic [125I]Bolton Hunter-cholecystokinin-8 binding. Co-incubation with the specific cholecystokininA and cholecystokininB antagonists, devazepide and CI-988, indicated that in the rat cholecystokininB receptor binding markedly increased, with a small increase in cholecystokininA receptor binding. In the mouse the response was comprised solely of cholecystokininA receptors. In situ hybridization studies were carried out on a range of peptide messenger ribonucleic acids after salt-loading. In the rat large increases in hypothalamic gene expression were detected for oxytocin, vasopressin, corticotrophin-releasing factor and preprocholecystokinin. In the mouse only vasopressin messenger ribonucleic acid increased, whilst hypothalamic oxytocin, preprocholecystokinin and corticotropin-releasing factor remained unchanged. However, corticotrophin-releasing factor messenger ribonucleic acid increased in the mouse amygdala. In situ hybridization was performed using oligonucleotide probes specific for either the cholecystokininA or cholecystokininB receptor messenger ribonucleic acid, and this showed good agreement with the receptor autoradiography. CholecystokininB receptor expression was upregulated in the rat hypothalamus along with a small but significant increase in cholecystokininA receptors. In the mouse only cholecystokininA receptor expression was increased. In addition to these molecular changes rats lost about 25% of their body weight during six days of salt-challenge, whilst mice continued to grow in line with controls. This work demonstrates differential changes in cholecystokinin receptor subtype binding between the rat and the mouse. It represents the first report of differential changes in cholecystokininA and cholecystokininB receptor messenger ribonucleic acids within the brain, and shows that cholecystokinin receptors within the rodent hypothalamus are capable of plastic responses to chronic osmotic stress.

Increase in cortical procholecystokinin gene expression induced by a meningo-cortical injury: studies on the involvement of the "immediate early gene" c-fos

In rat cortex, a meningo-cortical injury causes complex changes in the expression of the "immediate early" genes c-fos and c-jun as well as the neuropeptide gene procholecystokinin. Within 1 h, mRNA levels of c-fos and c-jun are enhanced. Three hours later they have returned to control values. Twenty-four hours after the injury, there is a second rise in the level of c-fos-mRNA, which is accompanied by an increase in procholecystokinin-mRNA. In the present study, it was investigated whether these events are causally connected. When MK-801 (1.5 mg/kg), an ion-channel blocker, was injected 7 and 19 h after the injury, i.e. after the first rise in expression of both "immediate early" genes, it prevented the later increase in procholecystokinin-mRNA. When given 30 min prior to the injury, MK-801 (4 mg/kg) prevented the increased expression of c-fos but did not affect the later rise in procholecystokinin-mRNA. In a third experiment the cortex injury was performed in a manner which did not increase procholecystokinin-mRNA in frontal cortex. Nevertheless, expression of the c-fos gene was enhanced when determined 24 h after the operation. It is concluded that the injury-induced rise in the expression of the procholecystokinin gene is not connected with the changes in c-fos-mRNA.